Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis
复制标题
DOI：
10.3324/haematol.11687
复制
发表时间：
2008-02-29
期刊：
影响因子：
10.1
通讯作者：
Schonland, Stefan O.
中科院分区：
文献类型：
--
作者：
Bochtler, Tilmann;Hegenbart, Ute;Schonland, Stefan O.
我们对 133 名未经治疗的系统性 AL 淀粉样变性患者进行了血清游离轻链 (FLC) 测试评估。 FLC 测试检测出 87% 的单克隆丙种球蛋白病，而血清和尿液联合免疫固定的检测结果为 92%。然而，这两项测试被证明是互补的。尽管不涉及轻链保留，FLC 测试对于晚期肾衰竭患者也是一个有价值的工具。较高的 FLC 水平与较高的骨髓浆细胞增多、较差的卡诺夫斯基指数和心脏受累相关，因此反映了疾病的严重程度。
We evaluated the Serum Free Light Chain (FLC) test in a series of 133 untreated patients with systemic AL amyloidosis. The FLC test detected the monoclonal gammopathy in 87% compared with 92% for immunofixation of serum and urine in combination. However, both tests proved complementary. The FLC test was also a valuable tool in patients with advanced renal failure in spite of uninvolved light chain retention. Higher FLC levels were associated with higher bone marrow plasmocytosis, poorer Karnofsky index and heart involvement, and therefore reflected disease severity.